Terumo Corporation
14
1
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
21%
3 trials in Phase 3/4
11%
1 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)
Role: collaborator
Safety and Efficacy of the Ultimaster Stent
Role: collaborator
Effect of Flexible Catheter Materials on Catheter Angle and Blood Vessel Irritation
Role: collaborator
RETRIEVE-AMI Study
Role: collaborator
Outcomes and Quality of Life Following Rectal Artery Embolization for Bleeding Internal Hemorrhoids
Role: collaborator
Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma
Role: collaborator
Oximetry Guided Versus Traditional Rapid Deflation Technique for Achieving Hemostasis After Radial Procedures
Role: collaborator
Effect of Ultimaster Stents Treated to the Most Dilated Coronary Vessels
Role: collaborator
WAMIF : Young Women Presenting Acute Myocardial Infarction in France
Role: collaborator
Evaluation of Effectiveness and Safety of NOBORI Stent
Role: collaborator
Registry in Korea: BioMimeTM Stent, Ultimaster® Stent vs. Xience® Stent
Role: collaborator
Using 3D Imaging to Optimize Bifurcation Stenting
Role: collaborator
European Bifurcation Club Trial - Two-stent Versus One-stent Technique for Large Bifurcation Lesions
Role: collaborator
Efficacy and Safety Study of Deferred Stenting in Patients With STEMI
Role: collaborator
All 14 trials loaded